RecruitingNCT07180056
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
Efficacy and Safety of Adjuvant CDK4/6 Inhibitors in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: a Real-world Study
Sponsor
Wenjin Yin
Enrollment
229 participants
Start Date
Aug 28, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Aged ≥18 and older
- Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence
- HR+/HER2-
- ECOG 0-3
- Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4/6 inhibitors
Exclusion Criteria2
- During pregnancy or lactation
- Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption
Interventions
DRUGCDK4/6 inhibitor
abemaciclib OR ribociclib
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07180056
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT052915071 location
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
NCT0693085934 locations